Soluble CD40 ligand in morbidly obese patients: Effect of body mass index on recovery to normal levels after gastric bypass surgery

JAMA Surgery

Volumn 148, Issue 2, 2013, Pages 151-156

  Baena Fustegueras, Juan A ^a   Pardina, Eva ^h   Balada, Eva ^b   Ferrer, Roser ^c   Catalán, Roberto ^c   Rivero, Joaquín ^g   Casals, Isidre ^h   Lecube, Albert ^d   Fort, Jose M ^e   Vargas, Víctor ^f   Peinado Onsurbe, Julia ^h  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b Systemic Autoimmune Diseases Unit   (Spain)

^c Biochemistry Department   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e Endocrinology Surgery Unit   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE; ARTICLE; BARIATRIC SURGERY; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MORBID OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CD40 LIGAND; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC BYPASS; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; PROGNOSIS; RECOVERY OF FUNCTION; WEIGHT LOSS;

EID: 84874226366     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurgery.2013.419     Document Type: Article

References (25)

1. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA. 2000;97(13):6930-6932.
2. Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol. 2005;25(2): 103-121.
3. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106(8):896-899.
4. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Car-diovasc Med. 2002;12(1):27-32.
5. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-594.
6. Schönbeck U, Mach F, Sukhova GK, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156 (1):7-14.
7. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104(19):2266-2268.
8. Blake GJ, Ostfeld RJ, Yucel EK, et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol. 2003;23(1):e11-e14.
9. Heeschen C, Dimmeler S, Hamm CW, et al; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348 (12):1104-1111.
10. Aukrust P, Müller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100(6):614-620.
11. Santilli F, Basili S, Ferroni P, Davì G. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007;2(4):256-268.
12. Guldiken S, Guldiken B, Demir M, et al. Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain. 2011;12(3): 355-360.
13. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA. 2003;289(14):1781-1782.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-2497.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-419.
16. Pardina E, Lecube A, Llamas R, et al. Lipoprotein lipase but not hormone-sensitive lipase activities achieve normality after surgically induced weight loss in morbidly obese patients. Obes Surg. 2009;19(8):1150-1158.
17. Unek IT, Bayraktar F, Solmaz D, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res. 2010;8(2):89-95.
18. Schernthaner GH, Kopp HP, Krzyzanowska K, Kriwanek S, Koppensteiner R, Sch-ernthaner G. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest. 2006;36(6):395-401.
19. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119(1):79-84.
20. Hanusch-Enserer U, Zorn G, Wojta J, et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009;30 (12):1516-1524.
21. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002; 105(24):2849-2854.
22. Nagasawa M, Zhu Y, Isoda T, et al. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L. Eur J Haematol. 2005;74(1):54-60.
23. Michelson AD. How platelets work: platelet function and dysfunction. J Thromb Thrombolysis. 2003;16(1-2):7-12.
24. i family members in platelets: redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002;277(48):46035-46042.
25. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL III, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43(12):2319-2325.